These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 12540745)

  • 1. Telomere inhibition and telomere disruption as processes for drug targeting.
    Rezler EM; Bearss DJ; Hurley LH
    Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomeres and telomerases as drug targets.
    Rezler EM; Bearss DJ; Hurley LH
    Curr Opin Pharmacol; 2002 Aug; 2(4):415-23. PubMed ID: 12127874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere maintenance as a target for drug discovery.
    Sekaran V; Soares J; Jarstfer MB
    J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere maintenance mechanisms as a target for drug development.
    Bearss DJ; Hurley LH; Von Hoff DD
    Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Telomere and telomerase as targets for anti-cancer drugs].
    Ide T
    Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
    Maji B; Bhattacharya S
    Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
    Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
    Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase as an anti-cancer target: current status and future prospects.
    Neidle S; Kelland LR
    Anticancer Drug Des; 1999 Aug; 14(4):341-7. PubMed ID: 10625926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction.
    Yeo M; Rha SY; Jeung HC; Shen XH; Yang SH; An SW; Roh JK; Chung HC
    FEBS Lett; 2005 Jan; 579(1):127-32. PubMed ID: 15620701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere maintenance as a target for anticancer drug discovery.
    Neidle S; Parkinson G
    Nat Rev Drug Discov; 2002 May; 1(5):383-93. PubMed ID: 12120414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agents that target telomerase and telomeres.
    Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
    Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer therapy targeting telomeres and telomerase : current status.
    Parkinson EK; Minty F
    BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Cancer by Targeting Telomeres and Telomerase.
    Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N
    Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures.
    Kim MY; Gleason-Guzman M; Izbicka E; Nishioka D; Hurley LH
    Cancer Res; 2003 Jun; 63(12):3247-56. PubMed ID: 12810655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prospects for targeting telomerase beyond the telomere.
    Arndt GM; MacKenzie KL
    Nat Rev Cancer; 2016 Aug; 16(8):508-24. PubMed ID: 27339602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.